Pharmacy and Poisons Board warns of counterfeit diabetes drug in the market
Health & Science
By
Esther Nyambura
| Jul 18, 2024
Pharmacy and Poisons Board issues warning about counterfeit Ozempic Pens.
The Pharmacy and Poisons Board (PPB) has warned the public against using Ozempic Pens, also known as Semaglutide.
In a statement on Thursday, July 18, PPB noted it has not authorised or registered any Ozempic Pens for use in the Kenyan market.
According to the Board, healthcare providers are prescribing Apidra Solostar Pens, which are intended for treating type 1 and 2 diabetes and relabelling them as Ozempic Pens.
"The Pharmacy and Poisons Board wishes to draw the attention of the public to an alert concerning the falsification of Ozempic Pens where Apidra Solostar Pens have been relabelled as Ozempic Pens," read the statement.
READ MORE
New KRA boss Muriithi wants outdated annual Finance Bill scrapped
KTDA focuses on tea quality as weekly auction generates Sh1.6 billion
Directline insurance moves to repair image amid shareholder wrangles
Kenya-UAE deal could be a catalyst for job creation and an economic booster
Survey reveals housing project has missed the mark, is doomed to fail
TikTok's US future in limbo after Supreme Court ruling
End of the road for CMC Motors as auto dealer to close shop
Prateek Suri: How the richest Indian billionaire in Africa is increasing ties through innovation
Scientifically, Ozempic Pens are used to lower blood sugar levels by helping the pancreas produce more insulin. They are primarily used as a treatment for type 2 diabetes.
However, some individuals use them for weight loss, despite not being approved for this purpose.
The Board has expressed concern that using falsified Ozempic Pens could jeopardise public health and safety.
PPB urged Kenyans to exercise caution and avoid trading or administering these pens until proper surveillance of the product currently in the market is completed.